The in vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann's thrombasthenia

Platelets

Volumn 23, Issue 8, 2012, Pages 604-610

  Shenkman, Boris ^a   Livnat, Tami ^a   Misgav, Mudi ^a   Budnik, Ivan ^b   Einav, Yulia ^c   Martinowitz, Uriel ^a  

^a The Amalia Biron Research Institute of Thrombosis and Hemostasis   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HOLON INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Factor XIII; Fibrinogen; Glanzmann's thrombasthenia; Thrombin generation; Thromboelastometry

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR 13 CONCENTRATE; CALCIUM CHLORIDE; EPTIFIBATIDE; FIBRINOGEN CONCENTRATE; THROMBIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 13; FIBRINOGEN; PEPTIDE;

AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; FIBRINOLYSIS; GLANZMANN DISEASE; HUMAN; IN VIVO STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; ROTATION THROMBOELASTOMETRY; SENSITIVITY AND SPECIFICITY; SPIKE WAVE; THROMBIN TIME; THROMBOCYTE RICH PLASMA; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY; BLOOD; CASE CONTROL STUDY; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; METABOLISM;

AREA UNDER CURVE; BLOOD COAGULATION; CALCIUM CHLORIDE; CASE-CONTROL STUDIES; FACTOR XIII; FIBRINOGEN; HUMANS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET-RICH PLASMA; THROMBASTHENIA; THROMBELASTOGRAPHY; THROMBIN; THROMBIN TIME; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84868625269     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2011.642031     Document Type: Article

References (36)

1. George JN, Caen J-P, Nurden AT. Glanzmann's thrombasthenia: The spectrum of clinical disease. Blood 1990;75:1383-1395.
2. Caen JP. Glanzmann's thrombasthenia. Baillieres Clin Haematol 1989;2:609-625.
3. Savage B, Cattaneo M, Ruggeri ZM. Mechanisms of platelet aggregation. Curr Opin Hematol 2001;8:270-276.
4. Zwaal RFA, Comfurius P, Bevers EM. Lipid-protein interactions in blood coagulation. Biochem Biophys Acta 1998;1376: 433-453.
5. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ, Emili A, Fitzgerald DJ, Maquire PB. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004;103:2096-2104.
6. Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, Minford A, Mumford AD, Parapia LA, Perry DJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603-633.
7. Laursen B, Jacobsen SE, Taaning E, Grunnet N. Transfusion problems in patients with Glanzmann's thrombasthenia. Eur J Haematol 1992;49:143-144.
8. Poon M-C, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann's thrombasthenia. Blood 1999;94:3951-3953.
9. Poon MC. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia. Vasc Health Risk Manag 2007;3:655-664.
10. Di Minno G, Coppola A, Di Minno MND, Poon M-C. Glanzmann's thrombasthenia (defective platelet integrin -IIb- -3): Proposals for management between evidence and open issues. Thromb Haemost 2009;102:1157-1164.
11. Valentino LA. Use of rFVIIa in 4 children with Glanzmann thrombasthenia. J Pediatr Hematol Oncol 2004;28:653-658.
12. Dargaud Y, Bordet JC, Trzeciak MC, Vinciguerra C, Negrier C. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor VIIa during a surgical procedure: Observations on the monitoring and the mechanism of action of this drug. Haematologica 2006;91(6 Suppl):ECR20.
13. Eduran E, Aksoy A, Zaman D. The use of recombinant FVIIa in a patient with Glanzmann thrombasthenia with uncontrolled bleeding after tonsillectomy. Blood Coagul Fibrinolysis 2009;20:215-217.
14. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 1997;90:2515-2521.
15. Coppola A, Di Minno G. Desmopressin (DDAVP) in inherited disorders of platelet function. Haemophilia 2008;14(Suppl. 1): 31-39.
16. Lombardo VT, Sottliota G. Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extraction in a patient with Glanxmann's thrombasthenia. Clin Appl Thromb Hemost 2006;12:115-116.
17. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Bequin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4-15.
18. Velik-Salchner C, Haas T, Innerhofer P, Streif W, Nussbaumer W, Kingler A, Kilma G, Martinowitz U, Fries D. The effect of fibrinogen concentrate on thrombocytopenia. J Thromb Haemost 2007;5:1019-1025.
19. Johansson PI, Svendsen MS, Salado J, Bochsen L, Kristensen AT. Investigation of the thrombin-generating capacity, evaluated by thrombogram, and clot formation evaluated by thromboelastography of platelets stored in the blood bank for up to 7 days. Vox Sanguinis 2008;94:113-118.
20. Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS. Evaluation of rotation thromboelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008;100:792-797.
21. Chen A, Teruya J. Global hemostasis testing thromboelastography: Old technology, new applications. Clin Lab Med 2009;29:391-407.
22. Fenger-Eriksen C, Anker-Moller E, Heslop J, Ingerslev J, Sorensen B. Thromboelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anesth 2005;94:324-329.
23. Fries D, Innerhofer P, Reif C, Streif W, Klinger A, Schobersberger W, Velik-Salchner C, Friesennecker B. The effect of fibrinogen substitution on reversal of dilutional coagulopathy: An in vitro model. Anesth Analg 2006;102: 347-351.
24. Haas T, Fries D, Velik-Salchner C, Reif C, Klinger A, Innerhofer P. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution. Anesth Analg 2008;106:1360-1365.
25. Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: An in vitro model. Brit J Anaesth 2009;102:793-799.
26. Misgav M, Shenkman B, Budnik I, Einav Y, Martinowitz U. Differential roles of fibrinogen and von Willebrand factor on clot formation and platelet adhesion in reconstituted and immune thrombocytopenia. Anesth Analg 2011;112:1034-1405.
27. Male C, Koren D, Eichelberger B, Kaufmann K, Panzer S. Monitoring survival and function of transfused platelets in Glanzmann thrombasthenia by flow cytometry and thrombelastography. Vax Sang 2006;91:174-177.
28. Tanaka KA, Taketomi T, Szlam F, Calatzis A, Levy JH. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (haemocomplettan P). Anesth Analg 2008;106:732-738.
29. Walker JB, Bajzar L. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: The role and requirement of plasmin inhibitors. J Thromb Haemost 2007;5:1257-1264.
30. Muszbek L, Bagoly Z, Bereczky Z, Katona E. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem 2008;6:190-205.
31. Schramko AA, Kuitunen AH, Suojaranta-Yinen RT, Niemi TT. Role of fibrinogen-, factor VIII- and XIII-mediated clot propagation in gelatin-haemodilution. Acta Anaesth Scand 2009;53:731-735.
32. Theusinger OM, Bauling W, Asmis LM, Seifert B, Spahn DR. In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM). Thromb Haemost 2010;104:385-391.
33. Bolliger D, Szlam F, Levy JH, Molinaro RJ, Tanaka KA. Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage. Br J Anaesth 2010;104:318-325.
34. Vucellic D, Milijc P, Antonijevic N, Ilicevic M. The role of rotational thromboelastometry in real time assessment of haemostasis in surgical settings. Srp Arch Celok Lek 2010;138(Suppl. 1):43-49.
35. Lison S, Spannag M, Heind B. Perioperative haemostatic management of Glanzmann thrombasthenia for abdominal surgery. Blood Coagul Fibrinolysis 2009;20:371-373.
36. Lang T, Bauters A, Braun SL, Pötzsch B, von Pape KW, Kolde HJ, Lakner M. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinol 2005;16:301-310.